Navigation Links
Pipeline/Commercial Insight: Supportive Care in Oncology - Innovation and Market Growth Limited to Bone Metastases Management and Emerging Supportive Care Challenges Reports Now Available on ReportsandReports

DALLAS, February 16, 2010 /PRNewswire/ --

- ReportsandReports announce to have Pipeline/Commercial Insight: Supportive Care in Oncology - Innovation and market growth limited to bone metastases management and emerging supportive care challenges ( upportive-care-in-oncology-innova/) Market Research Report in its store

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

Supportive care in oncology is defined as those products used to prevent and/or treat the adverse side effects that arise as a result of the tumor itself or administration of anticancer therapies The supportive care market is potentially vast, therefore this report focuses on the cytopenias (anemia, neutropenia and thrombocytopenia), chemotherapy-induced nausea and vomiting, and bone metastases.


    - In-depth analysis of the current and future oncology supportive care
      market across the US, 5EU and Japan, plus a rest of world snapshot
    - Oncology supportive care therapy sales forecasts for brands, generics,
      biosimilars and late-phase pipeline candidates from 2008 to 2018
    - Assessment of the leading supportive care brands and drug classes to
      identify key success factors within this sector
    - Examination of the oncology supportive care pipeline with in-depth
      clinical and commercial profiles of Phase III candidates


The supportive care market will shrink at a CAGR of -0.6%, with sales dropping from $10.3 billion in 2008 to $9.3 billion in 2018. This is due to the effect of patent expiry and generic/biosimilar erosion, as well ongoing restrictions on use of erythropoietins. Pipeline launches during this time will be insufficient to offset this sales decline.

In 2008, Neulasta (pegfilgrastim; Amgen/Kyowa Kirin) and Neupogen (filgrastim; Amgen/Kyowa Kirin) were the leading supportive care brands, with sales well over $1 billion. Despite facing patent expiry and the increasing threat of biosimilar entry, Neulasta and Neupogen will remain in the top three in 2018, along with Prolia (denosumab; Amgen).

Growth in the market will come mainly from expanded use of current products into new indications and markets. The current pipeline is relatively sparse, however, the greatest breakthrough will occur via Prolia (denosumab; Amgen) for bone metastases. The greatest future growth will come from development in emerging supportive care challenges.

    Reasons to Purchase

    - Quantify the performance of each of the marketed oncology supportive
      care brands in the seven major markets over the period 2008 to 2018
    - Acquire a detailed account of oncology supportive care brand dynamics
      and the events that drive and limit their market growth
    - Benchmark the oncology supportive care brands against their
      generics/biosimilars and align their 7MM performance with a rest of
      world snapshot

    Related Reports

    - What's Next in Vaccines? HIV, Malaria, Rabies, MRSA, and 30 Other
      Vaccine Targets in the 2010-2020 Pipeline
    - Abraxis BioScience, Inc.-Detailed Product Pipeline
    - Accentia Biopharmaceuticals Inc-Detailed Product Pipeline

About Us

ReportsandReports, comprising of an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts of almost all well-known publishers of such reports across the globe. We, as a third-party reseller of market research reports, employ number of marketing tools such as press releases, email-marketing and effective search engine optimization technique to drive revenues for our clients. We also provide 24/7 online and offline support to our customers.


    Ms. Sunita
    7557 Rambler road
    Suite 727, Dallas, TX 75231
    Tel: +1-888-989-8004

SOURCE MarketsandMarkets

SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Supportive Oncology Services Accrues One Million Cancer Patient Self-Reported Assessments
2. SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
3. Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
4. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
5. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
6. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
7. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
8. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
9. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
10. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
11. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
Post Your Comments:
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Therapeutic Drug Monitoring ... Forecasts, Competitive Intelligence, Emerging Opportunities"  report ... ) has announced the addition ...
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Marker Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
(Date:11/25/2015)... WOODBURY, N.Y. , Nov. 25, 2015  Linden ... access and optimizing treatment outcomes for patients suffering from ... its request for a Temporary Restraining Order (TRO) enjoining ... between the two companies. --> ... aggressively pursuing all of its legal options. ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... TyloHelo ... parts and accessories. , Sauna accessories help improve the bather experience in the ... From basic styles for the purist looking for simplicity in design to accessories ...
(Date:11/25/2015)... ... 2015 , ... For the first time, Vitalalert is donating half of its ... The partnership between the two groups began in 2014 with Vitalalert pledging a portion ... International was founded in 1954 and is an international Christian-based health organization whose mission ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, ... for the Narconon network, announced the release of a new cutting edge recovery program ... organization has been working with drug- and alcohol-addicted individuals with the purpose to free ...
(Date:11/25/2015)... ... November 25, 2015 , ... Smiles by Stevens ... Disorder, Bruxism, and moderate facial wrinkling. While many patients are aware of the benefits ... great success Botox® delivers to those suffering with discomfort, soreness, and pain as a ...
(Date:11/25/2015)... Livonia, MI (PRWEB) , ... November 25, 2015 , ... ... at Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the ... the medical and surgical intensive care units (totaling 30 beds) from May 2014 through ...
Breaking Medicine News(10 mins):